Newark, New Castle, USA, Feb. 07, 2023 (GLOBE NEWSWIRE) -- As per the report published by Growth Plus Reports the Global RNAi Therapeutics Market was estimated at US$ 25.47 billion in 2021 and is expected to surpass a valuation of US$ 25.47 billion by 2030, progressing at a CAGR of 17% from 2022 to 2030. The report provides a detailed analysis of top winning strategies, drivers & opportunities, competitive scenario, wavering market trends, market size, statistics & estimations, and major investment pockets. Owing to the rising number of applications in molecular diagnostics, particularly in cancer and advancement in synthetic delivery carriers and chemical modifications to RNA.
Download PDF Brochure of RNAi Therapeutics Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.growthplusreports.com/inquiry/request-sample/rnai-therapeutics-market/8088
Market Drivers
The rising number of applications in molecular diagnostics, notably in cancer, as well as improved synthetic delivery carriers and chemical alterations to RNA, are driving market expansion. With the use of RNAi approaches in personalised medicine and molecular diagnostics, cancer detection and therapy are currently experiencing a paradigm change. Because of the availability of high throughput techniques for identifying changed cellular components and metabolites, RNAi techniques can be used in a variety of cancer detection and targeting approaches. According to an article published in March 2021 titled 'Insight into the Prospects for RNAi Therapy of Cancer,' RNAi knocks down the expression of target genes, locating these nodes that are essential to tumour maintenance, with minimal side effects and risk, blocking the inherent immunosuppression and triggering immune attacks on tumours. Furthermore, one of the benefits of RNAi technology is the rapid development of effective and tailored medications for tumour growth control. Small interfering RNAs (siRNA) or microRNAs (miRNA) can be used for diagnostic purposes.
Excerpts from ‘By Application Segmentation’
Based on application, the global RNAi therapeutics market has been segmented into:
- Oncology
- Ocular Disorders
- Respiratory Disorders
- Hepatitis B And C
- Autoimmune Hepatitis
- Neurological Disorders
- Others
The oncology segment dominated the market during forecast period. Recent advances, such as the development of nuclease-tolerant small interfering RNA (siRNA) and non-viral vectors, such as cationic liposomes and nanoparticles, can overcome this barrier and allow the clinical usage of RNAi-based treatments in the treatment of cancer. The market is likely to be driven by a significant pipeline of cancer therapeutics from firms and institutes such as Enzon Pharmaceuticals (Santaris Pharma), the University of Texas, OncoGenex, Isarna Therapeutics, Astrazeneca (Ionis Pharmaceuticals), and INSYS Therapeutics, Inc. For instance, Novartis got FDA clearance in December 2021 for Leqvio, a small interfering RNA (siRNA) therapy for low-density lipoprotein with two doses a year after an initial dosage and one at three months. Furthermore, several firms have engaged in research and development for nanocarriers to deliver oligonucleotides for cancer treatment, which is projected to contribute to the oncology vertical.
Excerpts from ‘By Region Segmentation’
Based on region, the global RNAi therapeutics market has been segmented into:
- North America
- Europe
- Asia Pacific
- Rest of the World
The North America is likely to create profitable prospects for market expansion. There are several RNAi therapies in the pipeline in the United States. A number of biotechnology firms have made significant investments in RNAi therapy development. Key pharmaceutical developers have gone into partnership or licence arrangements with a number of smaller firms in an effort to capitalise on the predicted revenue increase in this industry during the projection period. For example, AstraZeneca's partnership with Ionis Pharmaceuticals in December 2021 is one of the large deals that are actively investing in RNA-interference technology. Increasing approvals for RNAi therapy are projected to boost market expansion throughout the forecast period. For instance, Novartis got US Food and Drug Administration approval in December 2021 for Leqvio, the first and only small interfering RNA (SiRNA) therapy to low-density lipoprotein with two doses a year after an initial dosage and one at three months.
Browse Full Report with detailed TOC @ https://www.growthplusreports.com/report/rnai-therapeutics-market/8088
Excerpts from ‘Competitive Landscape’
Some of the prominent market players in the global RNAi therapeutics market include:
- Arcturus Therapeutics
- Argos Therapeutics Inc.
- AstraZeneca plc.
- Alnylam Pharmaceuticals
- BioNTech SE
- Curevac AG
- CRISPR Therapeutics AG
- Etherna Immunotherapies
- Ethris GMBH GSK plc.
- Ionis Pharmaceuticals, Inc
- Moderna Therapeutics
- CRISPR Therapeutics AG
- Nutcracker
- Pfizer Inc.
- Sanofi AG
- Sarepta Therapeutics
- Sangamo Therapeutics, Inc.
- Tiba Biotech
- Translate Bio, Inc
The key players are pursuing various growth strategies, such as product launches, acquisitions, and partnerships, which are contributing to the market's global expansion. On April 8, 2019, Regeneron Pharmaceuticals, Inc and Alnylam Pharmaceuticals, Inc announced a collaboration to discover, develop, and commercialise innovative RNA interference (RNAi) treatments for a wide range of disorders by targeting disease targets expressed in the eye and central nervous system (CNS). Additionally, the collaboration will expand on Alnylam's recent preclinical research showing robust and highly durable delivery of RNAi therapies to accomplish target gene silencing in the eye and CNS.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years - 2020
- Base Years - 2021
- Forecasted Years – 2022 to 2030
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trend (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL RNAi THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DISEASE TYPE
- RNA interference (RNAi)
- RNA Antisense
- GLOBAL RNAi THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY APPLICATION
- Oncology
- Ocular Disorders
- Respiratory Disorders
- Hepatitis B and C
- Autoimmune Hepatitis
- Neurological Disorders
- Other
TOC Continued..
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
View all healthcare related reports here : https://www.growthplusreports.com/report-store
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
